Advertisement

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Roche. (6/5/17). "Press Release: APHINITY Study Shows Roche’s Perjeta-based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-positive Early Breast Cancer". Basel.

Organisations Organisation Roche (Group)
  Organisation 2 Breast International Group (BIG)
Products Product Perjeta™
  Product 2 clinical research
Person Person Horning, Sandra (Roche 201401–201912 CMO + Head Global Product Development joined 2009 RETIRED 12/19)
     


   
Record changed: 2023-06-05

Advertisement

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Roche (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px




» top